Anatara Lifesciences Ltd (ASX:ANR) Receives Ethics Approval to Start IBS Trial
Anatara Receives Ethics Approval to Start IBS TrialMelbourne, Feb 8, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).
Highlights:
- Study design is Randomised, Double-Blinded and Placebo-Controlled to address future evidence-based claims
- Virtual study with ObvioHealth Australia to provide digital clinical trial platform ClaimIt
- Supported by leading CROs: GenesisCare Clinical CRO, Microba, Sonic Clinical Trials
Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline
News provided by
Share this article
Share this article
NEW YORK, Feb. 2, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications.
Drug Pipeline Highlights:
HT-001: Granted Pre-IND meeting with FDA with responses targeted for February 22, 2021
HT-003: Received positive preclinical mechanism of action date for acne treatment and renewal of the preclinical research plan
HT-004: Key proof-of-concept animal model data expected in Q2 2021
Mr. Robb Knie, Chief Executive Officer of Hoth, commented, Hoth s entire pipeline of innovative novel therapeutics have made significant progress throughout their developmental process over the course of the last year. During that time, we have been able to strengthen our balance shee
Algernon Pharmaceuticals Provides Year End Summary of Key Activities
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year. NP-120 Idiopathic Pulmonary Fibrosis & Chronic Cough Clinical Research Program March 30 – Submitted for ethics approval in Australia for a Phase 2 study of the Company’s re-purposed drug Ifenprodil for IPF and chronic cough. May 6 – …
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year.
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
News provided by
Share this article
Share this article
NEW YORK, Dec. 10, 2020 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia.
The Company expects to dose the first subject during early 2021 and report top-line data from the first cohort of the trial in the first quarter of 2021, followed by initiation of dosing in patients with mild to moderate atopic dermatitis in the second quarter. Following the successful completion of the Phase 1b trial, the Company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the efficacy of B